Asset Details
Do you wish to reserve the book?
The Effect of Gabapentin Enacarbil on Quality of Life and Mood Outcomes in a Pooled Population of Adult Patients with Moderate-to-Severe Primary Restless Legs Syndrome
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The Effect of Gabapentin Enacarbil on Quality of Life and Mood Outcomes in a Pooled Population of Adult Patients with Moderate-to-Severe Primary Restless Legs Syndrome
Do you wish to request the book?
The Effect of Gabapentin Enacarbil on Quality of Life and Mood Outcomes in a Pooled Population of Adult Patients with Moderate-to-Severe Primary Restless Legs Syndrome
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The Effect of Gabapentin Enacarbil on Quality of Life and Mood Outcomes in a Pooled Population of Adult Patients with Moderate-to-Severe Primary Restless Legs Syndrome
2016
Overview
Objective
The aim was to assess gabapentin enacarbil (GEn) treatment effects on quality of life (QOL) and mood in adults with moderate-to-severe primary restless legs syndrome (RLS).
Methods
Data were pooled from three placebo-controlled, randomized, double-blind, 12-week trials for adults receiving GEn (600 mg or 1200 mg) or placebo once daily. QOL was assessed with the RLS QOL questionnaire in two studies. Mood was examined with the Profile of Mood States Brief Form (POMS-B), and as an exploratory analysis with International Restless Legs Scale (IRLS) item 9 (daily affairs) and item 10 (mood disturbance) across all three studies. Mood and QOL were secondary endpoints in the individual clinical trials. No adjustments for multiplicity were applied.
Results
The QOL analysis modified intent-to-treat (MITT) population included 541 adults (placebo,
n
= 204; GEn 600 mg,
n
= 114; GEn 1200 mg,
n
= 223). Both GEn doses significantly improved QOL versus placebo (week 12;
p
< 0.01). The mood analysis MITT population included 671 adults (placebo,
n
= 244; GEn 600 mg,
n
= 161; GEn 1200 mg,
n
= 266). GEn 600 mg significantly improved POMS vigor-activity versus placebo (week 12;
p
< 0.05); other POMS criteria were not significantly affected. GEn 1200 mg significantly improved POMS scores for total mood disturbance, depression-dejection, fatigue-inertia, vigor-activity, and confusion-bewilderment versus placebo at week 12 (
p
< 0.05); tension-anxiety and anger-hostility were not significantly affected. Both GEn doses significantly improved IRLS item 9 and item 10 versus placebo at week 12 (
p
< 0.05). The most frequent treatment-emergent adverse events with GEn were somnolence and dizziness.
Conclusions
GEn (600 mg and 1200 mg) once daily significantly improved QOL in adults with moderate-to-severe primary RLS at all time points examined. While the only POMS item significantly improved by GEn 600 mg versus placebo at week 12 was vigor-activity, GEn 1200 mg significantly improved total mood disturbance and several other POMS items versus placebo at week 12. Both QOL and mood improvements were numerically greater with GEn 1200 mg versus 600 mg.
Trial Registrations
Clinicaltrials.gov identifiers NCT00298623, NCT00365352, NCT01332305.
Publisher
Springer International Publishing,Springer Nature B.V
Subject
/ Carbamates - adverse effects
/ Carbamates - therapeutic use
/ Dose-Response Relationship, Drug
/ Ethics
/ Female
/ gamma-Aminobutyric Acid - adverse effects
/ gamma-Aminobutyric Acid - analogs & derivatives
/ gamma-Aminobutyric Acid - therapeutic use
/ Humans
/ Ligands
/ Male
/ Medicine
/ Membrane Transport Modulators - adverse effects
/ Membrane Transport Modulators - therapeutic use
/ Pain
/ Psychiatric Status Rating Scales
/ Psychotropic Drugs - adverse effects
/ Psychotropic Drugs - therapeutic use
/ Restless Legs Syndrome - drug therapy
/ Restless Legs Syndrome - psychology
/ Sleep
/ Studies
